IL-4 and IL-13 induce equivalent expression of traditional M2 markers and modulation of reactive oxygen species in human macrophages
In cardiovascular disease, pathological and protective roles are reported for the Th2 cytokines IL-4 and IL-13, respectively. We hypothesised that differential effects on macrophage function are responsible. Type I and II receptor subunit (IL-2Rγ, IL-4Rα and IL-13Rα1) and M2 marker (MRC-1, CCL18, CCL22) expression was assessed via RT-qPCR in IL-4- and IL-13-treated human primary macrophages. Downstream signalling was evaluated via STAT1, STAT3 and STAT6 inhibitors, and IL-4- and IL-13-induced reactive oxygen species (ROS) generation assessed. IL-4 and IL-13 exhibited equivalent potency and efficacy for M2 marker induction, which was attenuated by STAT3 inhibition. Both cytokines enhanced PDBu-stimulated superoxide generation however this effect was 17% greater with IL-4 treatment. Type I IL-4 receptor expression was increased on M1-like macrophages but did not lead to a differing ability of these cytokines to modulate M1-like macrophage superoxide production. Overall, this study did not identify major differences in the ability of IL-4 and IL-13 to modulate macrophage function, suggesting that the opposing roles of these cytokines in cardiovascular disease are likely to be via actions on other cell types. Future studies should directly compare IL-4 and IL-13 in vivo to more thoroughly investigate the therapeutic validity of selective targeting of these cytokines.
Top-30
Journals
|
1
2
3
4
5
|
|
|
Frontiers in Immunology
5 publications, 8.47%
|
|
|
International Journal of Molecular Sciences
4 publications, 6.78%
|
|
|
Scientific Reports
3 publications, 5.08%
|
|
|
Journal of Immunology
2 publications, 3.39%
|
|
|
Acta Biomaterialia
2 publications, 3.39%
|
|
|
Cancers
2 publications, 3.39%
|
|
|
Cell Reports
1 publication, 1.69%
|
|
|
Journal of Personalized Medicine
1 publication, 1.69%
|
|
|
Biomedicine and Pharmacotherapy
1 publication, 1.69%
|
|
|
Gastric Cancer
1 publication, 1.69%
|
|
|
MedComm
1 publication, 1.69%
|
|
|
Industrial Crops and Products
1 publication, 1.69%
|
|
|
Archives of Toxicology
1 publication, 1.69%
|
|
|
Nature Medicine
1 publication, 1.69%
|
|
|
International Journal of General Medicine
1 publication, 1.69%
|
|
|
Cardiovascular Toxicology
1 publication, 1.69%
|
|
|
Phytotherapy Research
1 publication, 1.69%
|
|
|
ACS Nano
1 publication, 1.69%
|
|
|
Applied Materials Today
1 publication, 1.69%
|
|
|
iScience
1 publication, 1.69%
|
|
|
Journal of Cellular and Molecular Medicine
1 publication, 1.69%
|
|
|
International Journal of Biological Macromolecules
1 publication, 1.69%
|
|
|
Materials Today Bio
1 publication, 1.69%
|
|
|
Allergy: European Journal of Allergy and Clinical Immunology
1 publication, 1.69%
|
|
|
Journal for ImmunoTherapy of Cancer
1 publication, 1.69%
|
|
|
mBio
1 publication, 1.69%
|
|
|
European Journal of Heart Failure
1 publication, 1.69%
|
|
|
Advanced Intelligent Discovery
1 publication, 1.69%
|
|
|
Journal of Physiology
1 publication, 1.69%
|
|
|
1
2
3
4
5
|
Publishers
|
2
4
6
8
10
12
|
|
|
Elsevier
12 publications, 20.34%
|
|
|
Springer Nature
10 publications, 16.95%
|
|
|
Wiley
10 publications, 16.95%
|
|
|
MDPI
8 publications, 13.56%
|
|
|
Frontiers Media S.A.
5 publications, 8.47%
|
|
|
Cold Spring Harbor Laboratory
3 publications, 5.08%
|
|
|
Oxford University Press
2 publications, 3.39%
|
|
|
Taylor & Francis
2 publications, 3.39%
|
|
|
American Chemical Society (ACS)
1 publication, 1.69%
|
|
|
BMJ
1 publication, 1.69%
|
|
|
American Society for Microbiology
1 publication, 1.69%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
1 publication, 1.69%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 1.69%
|
|
|
Royal Society of Chemistry (RSC)
1 publication, 1.69%
|
|
|
Tsinghua University Press
1 publication, 1.69%
|
|
|
2
4
6
8
10
12
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.